Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011;64(4):218-22.
doi: 10.5173/ceju.2011.04.art6. Epub 2011 Dec 9.

The impact of adjuvant therapy in patients with biochemical recurrence on prostate cancer progression and mortality five years after radical prostatectomy

Mieczysław Fryczkowski  1 , Piotr Bryniarski  1 , Maciej Szczębara  1 , Marian Suchodolski  1 , Andrzej Paradysz  1
Affiliations

The impact of adjuvant therapy in patients with biochemical recurrence on prostate cancer progression and mortality five years after radical prostatectomy

Mieczysław Fryczkowski et al. Cent European J Urol. 2011.

Abstract

Introduction: The clinical significance of biochemical recurrence (BCR) after radical prostatectomy (RP) due to prostate cancer (PCa) is not unambiguous, sometimes being independent from the real progression. BCR is followed by a greater risk of adverse events and almost always results with the necessity for implementation of adjuvant therapy (AT). The aim of the following study was to examine the impact of AT in patients with BCR together with PCa progression and mortality 5-years after RP.

Material and methods: Two hundred forty-seven patients after RP, who were treated in the period from 1995 to 2009, underwent the retrospective analysis. They were divided into three groups according to the applied AT after prior BCR diagnosis. The first group (n - 39) included patients treated with radiotherapy, along with hormonotherapy. The second group (n - 63) covers patients receiving hormonotherapy only. The third group (n - 145) consists of patients without BCR. Five-year general and disease-specific survival was evaluated and choice prognostic factors were compared.

Results: Five-year overall survival was 74.2% in group I, 88.3% in group II, and 98.7% in group III. Diseasespecific survival was: 76.9%, 90.5%, and 100% (p = 0.001), respectively. BCR was diagnosed in 102 (41.5%) patients; while in another 24 (23.5%) of them progression was diagnosed after the AT was applied.

Conclusions: The risk of BCR 5-years after RP is greater in patients with high initial concentration of PSA, higher Gleason score, and clinical advancement. Five-year overall and disease-specific survivals are higher among patients after hormonotherapy alone compared to those after both radio- and hormonotherapy.

Keywords: cancer; hereditary prostate; prostate; prostate cancer.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Clinical advancement of PCa in groups depending on AT.
Fig. 2
Fig. 2
Clinical advancement of PCa in patients depending on cancer progression.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ward JF, Moul JW. Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer. Curr Opin Urol. 2005;15:187–195. - PubMed
    1. Koch MO, Foster RS, Bell B, et al. Characterization and predictors of prostate specific antigen progression rates after radical retropubic prostatectomy. J Urol. 2000;164:749–753. - PubMed
    1. Pound CR, Partin AW, Eisenberger MA, Chan DW, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591–1597. - PubMed
    1. Graefen M, Noldus J, Pichlmeier U, et al. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics. Eur Urol. 1999;36:21–30. - PubMed
    1. Djavan B, Sesterchenn I, Hruby S, Marberger M. Benign prostate glands in the surgical margin of radical prostatectomy: Redefining PSA nadir. J Urol. 2000;163(Suppl 4) abs 625.

LinkOut - more resources